The future of TCR-Treg therapies is renewables.
This review highlights emerging solutions for closed, automated and decentralised production, and discusses allogeneic approaches using gene-edited or banked Tregs with HLA engineering or matching with potential to provide safe, affordable tolerance-restoring therapies for autoimmune disease.